Altimmune, Inc., a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, focuses on developing peptide-based treatments for obesity and liver diseases and has subsidiaries globally. Its leading products, pemvidutide and HepTcell, are undergoing Phase II clinical trials in multiple countries for various indications.
David Drutz sold 16,011 shares of ALT on 19 August at $6.88 per share, worth a total of $110K. They now own 55,524 ALT shares, or a 28% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
